| |
|
Cancer of the Prostate |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
It is estimated that 186,320 men will be diagnosed with and 28,660 men will die of cancer of the prostate in 20081. The following information is based on NCI’s SEER Cancer Statistics Review2. Incidence & MortalitySEER IncidenceFrom 2001-2005, the median age at diagnosis for cancer of the prostate was 68 years of age3. Approximately 0.0% were diagnosed under age 20; 0.0% between 20 and 34; 0.6% between 35 and 44; 8.6% between 45 and 54; 28.0% between 55 and 64; 36.1% between 65 and 74; 22.0% between 75 and 84; and 4.7% 85+ years of age. The age-adjusted incidence rate was 163.0 per 100,000 men per year. These rates are based on cases diagnosed in 2001-2005 from 17 SEER geographic areas.
US MortalityFrom 2001-2005, the median age at death for cancer of the prostate was 80 years of age4. Approximately 0.0% died under age 20; 0.0% between 20 and 34; 0.1% between 35 and 44; 1.4% between 45 and 54; 6.9% between 55 and 64; 20.4% between 65 and 74; 41.5% between 75 and 84; and 29.7% 85+ years of age. The age-adjusted death rate was 26.7 per 100,000 men per year. These rates are based on patients who died in 2001-2005 in the US.
Trends in RatesTrends in rates can be described in many ways. Information for trends over a fixed period of time, for example 1995-2005, can be evaluated by the annual percentage change (APC) (See Fast Stats for trends over fixed time intervals). If there is a negative sign before the number, the trend is a decrease; otherwise it is an increase. If there is an asterisk after the APC then the trend was significant, that is, one believes that it is beyond chance, i.e. 95% sure, that the increase or decrease is real over the period 1995-2005. If the trend is not significant, the trend is usually reported as stable or level. Joinpoint analyses can be used over a long period of time to evaluate when changes in the trend have occurred along with the APC which shows how much the trend has changed between each of the joinpoints.
Survival & StageSurvival rates can be calculated by different methods for different purposes. The survival rates presented here are based on the relative survival rate, which measures the survival of the cancer patients in comparison to the general population to estimate the effect of cancer. The overall 5-year relative survival rate for 1996-2004 from 17 SEER geographic areas was 98.9%. Five-year relative survival rates by race were: 99.5% for white men; 95.4% for black men. The stage distribution based on historic stage shows that 91% of prostate cancer cases are diagnosed while the cancer is still confined to the primary site or after the cancer has spread to regional lymphnodes (localized or regional stage); 4% are diagnosed after the cancer has already metastasized (distant stage) and for the remaining 4% the staging information was unknown. The corresponding 5-year relative survival rates were: 100.0% for localized/regional; 31.7% for distant; and 79.4% for unstaged. (See Fast Stats for more detailed statistics) Lifetime RiskBased on rates from 2003-2005, 15.78% of men born today will be diagnosed with cancer of the prostate at some time during their lifetime. This number can also be expressed as 1 in 6 men will be diagnosed with cancer of the prostate during their lifetime. These statistics are called the lifetime risk of developing cancer. Sometimes it is more useful to look at the probability of developing cancer of the prostate between two age groups. For example, 8.04% of men will develop cancer of the prostate between their 50th and 70th birthdays. (See Fast Stats for more detailed statistics, and Probability of Developing and Dying of Cancer for methodology) PrevalenceOn January 1, 2005, in the United States there were approximately 2,106,499 men alive who had a history of cancer of the prostate. This includes any person alive on January 1, 2005 who had been diagnosed with cancer of the prostate at any point prior to January 1, 2005 and includes persons with active disease and those who are cured of their disease. Prevalence can also be expressed as a percentage and it can also be calculated for a specific amount of time prior to January 1, 2005 such as diagnosed within 5 years of January 1, 2005. (See Fast Stats for more detailed statistics, and Overview of Prevalence Statistics for methodology) ReferencesAll statistics in this report are based on SEER incidence and NCHS mortality statistics. Most can be found within: Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, Mariotto A, Miller BA, Feuer EJ, Altekruse SF, Lewis DR, Clegg L, Eisner MP, Reichman M, Edwards BK (eds). SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||